Drug class in one race
PD-1 + VEGFA drugs for Non-Small Cell Lung Cancer
2 tracked PD-1 + VEGFA drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the PD-1 + VEGFA page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
1 Phase 31 Phase 2
Head-to-head evidence: Ivonescimab vs JS207